Iradimed (IRMD) Gross Margin (2013 - 2026)

Iradimed (IRMD) has 14 years of Gross Margin data on file, last reported at 76.5% in Q1 2026.

• On a quarterly basis, Gross Margin rose 43.0% year-over-year to 76.5% in Q1 2026; TTM through Mar 2026 was 76.84%, a 8.0% decrease from a year earlier, with the FY2025 full-year figure at 76.75%, down 19.0% from the prior year.
• Gross Margin for Q1 2026 stood at 76.5%, up from 75.06% in the prior quarter.
• Over the last five years, Gross Margin for IRMD reached as high as 79.71% in Q2 2022 and fell as low as 75.06% in Q4 2025.
• Historically, Gross Margin has averaged 76.9% across 5 years, with a median of 76.5% in 2026.
• Across the five-year window, Gross Margin jumped 497 bps in 2022 and sank 416 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 75.49% in 2022, then increased by 2 bps to 76.86% in 2023, then fell by 1 bps to 76.13% in 2024, then declined by 1 bps to 75.06% in 2025, then climbed by 2 bps to 76.5% in 2026.
• Per Business Quant data, the three most recent Gross Margin figures were 76.5% in Q1 2026, 75.06% in Q4 2025, and 77.8% in Q3 2025.